Remission of type 2 diabetes in a hypogonadal man under long-term testosterone therapy

OBSERVATIONAL STUDY CASE-CONTROL (EPIDEMIOLOGY)
 | 
2017
Haider A
Haider KS
Saad F
Endocrinol Diabetes Metab Case Rep. 2017 Sep 4;2017
Summary

In daily practice, clinicians are often confronted with obese type 2 diabetes mellitus (T2DM) patients for whom the treatment plan fails and who show an inadequate glycemic control and/or no sustainable weight loss. Untreated hypogonadism can be the reason for such treatment failure.

This case describes the profound impact testosterone therapy can have on a male hypogonadal patient with metabolic syndrome, resulting in a substantial and sustained loss of body weight, pronounced improvement of all critical laboratory values and finally complete remission of diabetes.

Keywords
dyslipidemia
hypertension
coronary artery disease
CAD
classical cardiovascular disease
risk factors
blood pressure
lipids
glycemic control
obesity
testosterone undecanoate
nebido
Testosterone Preparation
testosterone undecanoate
  • PP-NEB-ALL-0347-1

Copyright © 2019,
Bayer AG

This website is intended to provide information to an international audience outside the USA and UK.

Page last modified Tue, 20/08/2019

Bayer logo